Titlebook: Immunogenicity of Biopharmaceuticals; Marco van de Weert,Eva Horn M?ller Book 2008 Springer-Verlag New York 2008 Biosimilar.drug.interfero

apiary

變化

dilute

an overview of the immune system and factors that may trigger the immune system, via detection of antibodies and clinical implications, to various case examples and the regulatory view on immunogenicity. .978-1-4419-2608-1978-0-387-75841-1

不給啤

PANEL

辯論的終結(jié)

Case Study: Immunogenicity of Interferon-Beta,quired for optimal and individualized therapies, and Ab detection induced during therapy. In an effort to assess the clinical relevance of in vitro Ab measurements, many investigators distinguish between ‘binding’ Abs (BAbs) and in vitro ‘neutralizing’ Abs (NAbs) even though such a distinction may n

Infusion

仔細(xì)閱讀

,Immune Reactions Towards Biopharmaceuticals – a General, Mechanistic Overview,

情愛(ài)

colloquial

Immunogenicity of Biopharmaceuticals: Causes, Methods to Reduce Immunogenicity, and Biosimilars,